Osteoporosis: History and Discovery

The history of osteoporosis is the story of a silent disease slowly becoming visible. For most of recorded medicine, brittle bones in the old were simply accepted as a fact of aging — described, but neither named nor explained. The word osteoporosis (“porous bone”) was coined by the French pathologist Jean Lobstein in the 1820s–1830s, after the English surgeon Sir Astley Cooper had observed that aging bones grow “thin in their shell and spongy in the texture.” A full century later, in 1941, Fuller Albright of Massachusetts General Hospital recognized a specific form — postmenopausal osteoporosis — and proposed that it stemmed from estrogen deficiency, a hypothesis that reshaped the field. The arrival of bone-density measurement in the 1980s and the World Health Organization’s T-score definition in 1994 finally allowed the disease to be diagnosed before a bone broke, and modern drug therapy followed. This page traces that long arc, distinguishing carefully between who named the condition, who explained it, and who learned to measure it.

Table of Contents

  1. Brittle Bones in the Ancient and Early Record
  2. Astley Cooper and Age-Related Bone Fragility
  3. Jean Lobstein and the Coining of “Osteoporosis”
  4. Pathology, Histology, and the X-Ray Era
  5. Fuller Albright and the Postmenopausal Link
  6. Learning to Measure Bone: From Photons to DEXA
  7. The 1994 WHO Definition and the T-Score
  8. A History of Treatment
  9. From Description to Prevention
  10. Research Papers and References
  11. Connections

Brittle Bones in the Ancient and Early Record

That bones grow fragile with age is one of the oldest observations in medicine, even though the disease behind it went unnamed for millennia. Skeletal remains from antiquity — including Egyptian mummies and archaeological collections studied by modern paleopathologists — show the collapsed vertebrae, bowed spines, and healed hip fractures that we now recognize as the signature of severe bone loss. The stooped posture of the very old, sometimes called the “dowager’s hump,” was a familiar sight in every era, and classical and medieval physicians described the increasing brittleness of aged bones in general terms. What they lacked was any concept of osteoporosis as a distinct disorder of the bone itself; frailty of the skeleton was folded into the broader, fatalistic idea that the whole body simply dried out and weakened with the years.

For practical purposes, the consequences — not the cause — were what mattered to early medicine. A broken hip in an elderly person was often a death sentence in the pre-surgical, pre-antibiotic world, because the immobility it forced led to pneumonia and clots. Physicians could set fractures and prescribe rest, but they had no way to see the disease coming and no framework that distinguished a bone weakened by porosity from a bone weakened by other causes. The story of osteoporosis as a named, understood condition therefore really begins in the nineteenth century, when the new sciences of pathological anatomy and, later, radiology gave physicians the tools to look inside the bone and describe what they found.

Back to Table of Contents

Astley Cooper and Age-Related Bone Fragility

One of the clearest early clinical descriptions came from the celebrated English surgeon Sir Astley Paston Cooper (1768–1841). In his influential work A Treatise on Dislocations and on Fractures of the Joints, first published in 1822, Cooper drew direct attention to the way bone deteriorates in old age. In a frequently quoted passage he observed that in the elderly the bones “become thin in their shell and spongy in their texture,” and he linked this softening explicitly to the increased tendency of older people to suffer fractures — especially fractures of the neck of the femur (the hip) following only moderate falls or trauma.

Cooper’s contribution was clinical observation rather than naming or explanation: he did not coin a term for the condition, nor did he identify its cause. What he did was state plainly, on the basis of his vast surgical and anatomical experience, that age-related bone fragility was real, common, and the reason elderly hips broke so easily. This is an important distinction to preserve. Cooper described the phenomenon — brittle, porous, fracture-prone bone in the old — a decade or so before the condition acquired the name by which we know it today.

His emphasis on the fragile femoral neck proved prophetic. The hip fracture remains, two centuries later, the most feared and most lethal consequence of osteoporosis, and much of modern osteoporosis medicine is organized around predicting and preventing exactly the injury Cooper singled out. In tracing the history of the disease, Cooper stands as the figure who sharpened the long-standing folk awareness of brittle old bones into a specific surgical observation, setting the stage for the pathologists who would soon give the condition a name.

Back to Table of Contents

Jean Lobstein and the Coining of “Osteoporosis”

The word itself was the work of Jean Georges Chrétien Frédéric Martin Lobstein (1777–1835), a German-born French pathologist and surgeon associated with the University of Strasbourg, where in 1819 he became a professor of pathological anatomy. Working in the 1820s and 1830s, Lobstein examined bones that were riddled with abnormally large holes — far more porous than healthy bone — and reached for a descriptive Greek-rooted term to capture what he saw. He combined osteon (bone) with poros (passage, pore) to produce osteoporosis, literally “porous bone.” In his writing of this period (his work on the subject is generally dated to the early 1830s, around 1833) he used the French form ostéoporose alongside the related term ostéopsathyrose (denoting bone fragility).

It is worth being precise about what Lobstein did and did not establish. He coined the name and described the gross appearance of porous, hole-filled bone as a pathologist sees it on the dissecting table. He did not describe osteoporosis as the specific clinical disease of progressive, fracture-causing bone loss that the modern definition captures, and he certainly did not connect it to hormones, menopause, or any single cause — that understanding lay more than a century in the future. Lobstein’s “osteoporosis” was an anatomical-descriptive term for porous bone of various origins, and the word was used loosely in that sense throughout the nineteenth century.

Lobstein left another mark on bone medicine as well: he gave an early description of the inherited brittle-bone disorder now called osteogenesis imperfecta type I, still sometimes referred to as “Lobstein’s disease.” His enduring legacy for our subject, however, is linguistic and conceptual — he provided the vocabulary. Once there was a word for porous bone, physicians and pathologists had a shared label around which observations could accumulate, and the slow work of turning a descriptive term into a defined disease could begin.

Back to Table of Contents

Pathology, Histology, and the X-Ray Era

Through the middle and later nineteenth century, the study of bone advanced on the back of the broader revolution in cellular pathology led by figures such as Rudolf Virchow. Investigators using the microscope began to distinguish the different ways bone could be diseased: the failure of the bone matrix to mineralize properly (the softening seen in rickets and osteomalacia, tied to what would later be understood as vitamin D deficiency) versus the loss of bone mass and architecture while what bone remained stayed normally mineralized. This distinction — defective mineralization on the one hand, defective quantity of otherwise-normal bone on the other — is fundamental, and getting it right was a prerequisite for understanding osteoporosis as its own entity rather than a vague synonym for “weak bones.”

The single greatest leap in seeing bone disease came at the very end of the century with Wilhelm Conrad Röntgen’s discovery of X-rays in 1895. For the first time, physicians could view the living skeleton without surgery, observe fractures, and note when bones appeared unusually radiolucent — that is, when they had lost enough mineral to look faint and washed-out on a radiograph. This was transformative, yet it carried a crucial limitation that shaped the next eighty years of the field: plain X-rays are insensitive to early bone loss. By the time thinning bone is obvious on an ordinary radiograph, a large fraction of bone mass — on the order of a third or more — has typically already been lost. The X-ray could confirm advanced osteoporosis and reveal the fractures it caused, but it could not catch the disease early, and it could not put a reliable number on how much bone a person had.

By the early twentieth century, then, medicine possessed a name (Lobstein’s), a clear clinical picture of fragile aged bone (Cooper’s tradition), a sharpening pathological distinction between soft bone and scarce bone, and an imaging tool that could see — but only late — the result. What was still entirely missing were two things that would define modern osteoporosis: an explanation of why certain people, especially older women, lost bone so dramatically, and a way to measure bone density precisely enough to diagnose the disease before a fracture announced it.

Back to Table of Contents

Fuller Albright and the Postmenopausal Link

The decisive conceptual breakthrough came from the American endocrinologist Fuller Albright (1900–1969) at Massachusetts General Hospital, one of the founding figures of clinical endocrinology. In a landmark paper published in the Journal of the American Medical Association in 1941 (“Postmenopausal Osteoporosis: Its Clinical Features,” JAMA 1941;116(22):2465–2474), Albright and colleagues analyzed a series of forty-two patients with osteoporosis and reported a striking pattern: the overwhelming majority were women who had passed through menopause or who had had their ovaries removed at a young age. The disease was not randomly distributed across the aging population — it clustered conspicuously in estrogen-deprived women.

From this observation Albright built the hypothesis that defines the field to this day: that postmenopausal osteoporosis is driven principally by the loss of ovarian estrogen, and that the underlying defect is one of bone formation — too little new bone being built — rather than a failure of mineralization. This was a genuinely new way of thinking. It reframed osteoporosis from a vague, inevitable consequence of old age into a specific endocrine disorder with an identifiable hormonal cause and, by implication, a possible hormonal treatment. Using the metabolic-balance techniques he helped pioneer, Albright went on to gather evidence that estrogen therapy improved calcium balance in such patients, and he is credited with early therapeutic use of estrogen for the condition.

It is important to label the estrogen-deficiency idea correctly for what it was at the time: a hypothesis — a brilliant, well-reasoned inference from a clinical pattern, not yet a mechanistically proven fact. Decades of subsequent research, including the later discovery of how estrogen restrains the bone-resorbing cells (osteoclasts), would go on to provide strong support for Albright’s central claim, and the question “was Albright right?” has been revisited explicitly in the modern literature, generally answering in his favor. But Albright himself proposed a model, and the elegance of that model — menopause removes estrogen, lack of estrogen lets bone loss accelerate — is precisely why his 1941 paper is regarded as the birth of the modern understanding of osteoporosis. He named and characterized postmenopausal osteoporosis as a clinical entity, more than a hundred years after Lobstein had named porous bone in the abstract.

Back to Table of Contents

Learning to Measure Bone: From Photons to DEXA

A disease you cannot measure is a disease you cannot reliably diagnose early, study in trials, or treat to a target — and for decades after Albright, that was osteoporosis’s central practical problem. Plain X-rays could not quantify bone. The breakthrough came from the development of absorptiometry, the idea of passing a beam of radiation through the body and measuring how much is absorbed by bone, since denser bone absorbs more. Beginning in the 1960s, single-photon absorptiometry (SPA), developed by John Cameron and James Sorenson, used a radioactive isotope source to measure bone mineral at peripheral sites such as the forearm. It was the first method that could put an objective number on bone density in a living person.

The peripheral skeleton, however, is not where the most dangerous fractures happen. To assess the spine and the hip — the clinically critical sites — researchers in the United States and Europe developed dual-photon absorptiometry (DPA) in the 1970s and into the 1980s, using a source emitting two different photon energies to separate bone from the overlying soft tissue. DPA could finally reach the spine and proximal femur, but in practice it was slow, the images were crude, and the radioactive sources decayed and had to be replaced regularly, limiting its precision and convenience.

The technology that made bone-density testing routine arrived when the decaying isotope source was replaced by an X-ray tube. Dual-energy X-ray absorptiometry — DEXA, now more often written DXA — was introduced in 1987 and approved by the U.S. Food and Drug Administration for clinical use in 1988. DXA was faster, more precise, delivered a very low radiation dose, and produced a stable, reproducible measurement of bone mineral density at the spine and hip. For the first time, clinicians could detect significant bone loss long before a fracture occurred and could track, in an individual patient, whether bone was being lost or maintained. DXA quickly became, and remains, the reference standard for diagnosing osteoporosis — the tool that turned Albright’s clinical entity into something a doctor could find with a quiet, fifteen-minute scan.

Back to Table of Contents

The 1994 WHO Definition and the T-Score

Having a precise number for bone density raised an obvious question: how low is low enough to be called “osteoporosis”? Before the 1990s there was no agreed answer, and in clinical practice a diagnosis of osteoporosis effectively required a fragility fracture to have already happened — the disease was defined by its damage. The pivotal step toward modern, fracture-preventing care was taken in 1994, when a World Health Organization (WHO) study group established operational diagnostic criteria based on bone mineral density measured by DXA.

The WHO group defined the now-ubiquitous T-score: a person’s bone mineral density expressed as the number of standard deviations above or below the mean of a healthy young-adult reference population of the same sex. The thresholds the group set have governed diagnosis ever since — a T-score at or above −1.0 is normal; between −1.0 and −2.5 is “osteopenia” (low bone mass); and at or below −2.5 is osteoporosis. A diagnosis of “severe” or “established” osteoporosis was reserved for a T-score at or below −2.5 in someone who had also sustained one or more fragility fractures.

The significance of the 1994 definition is hard to overstate. By tying the diagnosis to a measurable number rather than to a broken bone, it made it possible to identify people at high risk before they fractured and to intervene early — the very thing the X-ray era could never do. It standardized osteoporosis research worldwide, allowing clinical trials of new drugs to enroll patients by a common criterion and to measure success in comparable terms. It also, as a side effect, created the category of “osteopenia” and a large population of people now labeled as having low bone mass, which sparked ongoing debate about over-diagnosis and over-treatment. The criteria were originally derived for postmenopausal white women and have required careful adaptation for men, younger people, and other populations. Even so, the WHO T-score framework remains the backbone of how osteoporosis is diagnosed across the world today.

Back to Table of Contents

A History of Treatment

Treatment evolved roughly in step with understanding. The oldest and most foundational measures address the raw materials and signals of bone: adequate calcium and vitamin D. The recognition that vitamin D governs calcium absorption and bone mineralization — growing out of the early-twentieth-century conquest of rickets — established calcium-and-vitamin-D sufficiency as the bedrock on which all other osteoporosis therapy is built, even though these nutrients alone are usually not enough to treat established disease. Weight-bearing exercise and fall prevention round out the non-pharmacologic foundation.

The first targeted medical therapy followed directly from Albright’s hypothesis: estrogen, and later combined hormone (estrogen–progestogen) therapy, given to replace what menopause removed. For much of the later twentieth century, hormone therapy was a mainstay of preventing postmenopausal bone loss. Its role was substantially reassessed after the early-2000s Women’s Health Initiative trials clarified the cardiovascular and breast-cancer risk trade-offs of long-term combined hormone therapy, after which it was no longer recommended as a first-line treatment used purely for osteoporosis in most women — a reassessment covered in depth on this site’s Menopause and HRT page.

The class that came to dominate modern treatment is the bisphosphonates, drugs that bind to bone and powerfully inhibit the osteoclasts that resorb it. The very first bisphosphonate, etidronate, entered medical use in the 1960s (initially for other bone conditions such as Paget’s disease), but at sustained doses it impaired mineralization, which limited it. The breakthrough was the nitrogen-containing “amino-bisphosphonates,” far more potent and without that drawback. Alendronate (Fosamax) was approved by the U.S. FDA for postmenopausal osteoporosis in 1995, backed by large fracture-prevention trial data, and it became a defining therapy of the field; risedronate, ibandronate, and intravenous zoledronic acid (FDA-approved for osteoporosis in 2007) followed.

The twenty-first century added entirely new mechanisms. Denosumab, a monoclonal antibody against RANK ligand — a signaling molecule essential for osteoclast formation — offered a different way to switch off bone resorption. And in a long-sought reversal of strategy, anabolic agents that build new bone rather than merely slowing its loss reached the clinic: teriparatide (a fragment of parathyroid hormone), later abaloparatide, and the sclerostin-blocking antibody romosozumab. These bone-building drugs — discussed on the Denosumab, Romosozumab, and Teriparatide and bisphosphonates deep-dive pages — finally gave clinicians the power to add bone back to a depleted skeleton, completing a journey from passive supportive care to precise molecular intervention.

Back to Table of Contents

From Description to Prevention

Seen as a whole, the history of osteoporosis is a movement from describing a disease to preventing it. The ancients and Astley Cooper described brittle old bone; Lobstein gave porous bone its name; nineteenth-century pathology and Röntgen’s X-rays let physicians distinguish and glimpse it; Fuller Albright explained its commonest form as a hormonal disorder; absorptiometry and then DXA learned to measure it precisely; the 1994 WHO criteria turned that measurement into an early, standardized diagnosis; and a succession of drugs — calcium and vitamin D, hormones, bisphosphonates, denosumab, and the anabolic agents — gave medicine the means to slow, halt, and even reverse the bone loss. Each link in that chain was a separate achievement, and conflating them — crediting the namer with the explanation, or the measurer with the cure — obscures how genuinely incremental the progress was.

That incremental honesty matters because osteoporosis remains, even now, a partly silent epidemic: it causes no symptoms until a bone breaks, and millions of fragility fractures — of the hip, spine, and wrist — still occur worldwide every year, with hip fracture in particular carrying serious risk of disability and death. The historical lesson encoded in tools like DXA and the FRAX fracture-risk calculator is precisely the value of looking ahead of the fracture rather than waiting for it. The modern goal — identify the at-risk skeleton early, with a scan and a risk score, and strengthen it before it fails — is the direct descendant of two centuries of physicians slowly learning first to name, then to see, then to measure, and finally to mend the porous bone that Lobstein first labeled in the 1830s.

For the clinical picture, diagnosis, and current management of the disease today, see the main Osteoporosis page and its deep-dive articles on the DEXA scan and T-scores, postmenopausal osteoporosis, and calcium, vitamin D, and nutrition.

Back to Table of Contents

Research Papers and References

The references below document the key milestones in this history — Lobstein’s coinage, Cooper’s observation, Albright’s 1941 paper, the development of bone densitometry, the 1994 WHO criteria, and the major treatments. Where a stable DOI or PMID is available it is linked directly; otherwise a curated PubMed topic-search link is provided. Historical primary texts (Cooper’s Treatise and Lobstein’s pathology writings) are named in the article as historical sources. Each link opens in a new tab.

  1. Albright F, Smith PH, Richardson AM. Postmenopausal Osteoporosis: Its Clinical Features. JAMA. 1941;116(22):2465–2474. — doi:10.1001/jama.1941.02820220007002
  2. Riggs BL, Melton LJ 3rd. Fuller Albright: his concept of postmenopausal osteoporosis and what came of it. Clin Orthop Relat Res. 1991;(269):2–5. — PubMed: PMID 1864030
  3. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone (Albright’s estrogen hypothesis revisited). Recent Prog Horm Res. 2002;57:385–409. — doi:10.1210/rp.57.1.385
  4. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–1141. — doi:10.1002/jbmr.5650090802
  5. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (WHO Technical Report Series 843). Geneva: WHO; 1994. — PubMed: WHO 1994 fracture-risk criteria
  6. Blake GM, Fogelman I. The history of bone densitometry. Bone. 2017;104:54–60. — doi:10.1016/j.bone.2017.06.005
  7. Cameron JR, Sorenson J. Measurement of bone mineral in vivo: an improved method (single-photon absorptiometry). Science. 1963;142(3589):230–232. — doi:10.1126/science.142.3589.230
  8. Cummings SR, Cosman F, et al. A History of Pivotal Advances in Clinical Research into Bone and Mineral Diseases. J Bone Miner Res. 2018. — doi:10.1002/jbmr.3353
  9. Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women’s Health Initiative. Semin Reprod Med. 2014;32(6):454–462. — doi:10.1055/s-0034-1384629
  10. Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2–19. — doi:10.1016/j.bone.2011.04.022
  11. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture (Fracture Intervention Trial). Lancet. 1996;348(9041):1535–1541. — doi:10.1016/S0140-6736(96)07088-2
  12. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis (FREEDOM). N Engl J Med. 2009;361(8):756–765. — doi:10.1056/NEJMoa0809493
  13. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (teriparatide) on fractures in postmenopausal women. N Engl J Med. 2001;344(19):1434–1441. — doi:10.1056/NEJM200105103441904
  14. Lobstein and the history and origin of the term “osteoporosis” (etymology and historical perspective). — PubMed: osteoporosis history and Lobstein

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents